(i) In drug-refractory GP the addition of PP to GES substantially accelerated GET; (ii) The GET response in P-V group was the most impressive; (iii) Significant symptom reductions were achieved by both procedures; and (iv) PP added to GES may sustain better long-term symptoms control particularly in the P-V setting.

Preliminary data suggest that certain female populations, including pregnant and menopausal women and possibly women with polycystic ovarian syndrome, are more susceptible to coronavirus disease 2019 (COVID-19)–related morbidity.

No abstract